补脾益肾方对比氯沙坦治疗非糖尿病4期慢性肾脏病的随机对照试验
本研究为多中心、双盲、双模拟随机对照试验,纳入567例非糖尿病CKD4患者,1:1分配接受补脾益肾方或氯沙坦治疗48周。结果显示补脾益肾方组eGFR斜率下降更慢(组间均差-2.25 ml/min/1.73 m2/年,95%CI:-4.03,-0.47),复合终点风险更低(校正HR=0.61,95%CI:0.44,0.85),不良事件发生率无显著差异。
要点
- 补脾益肾方可能延缓非糖尿病CKD4患者肾功能下降,尤其前12周。
- 补脾益肾方降低死亡、血肌酐倍增、ESKD、卒中或心血管事件复合风险。
- 不良事件发生率与氯沙坦组无显著差异,但长期疗效需更长随访。
核心结论
- 补脾益肾方可能对非糖尿病CKD4患者在前12周及48周内具有肾脏保护作用,但需更长随访评估长期疗效。
研究设计与样本
- 多中心、双盲、双模拟、随机对照试验,2011年11月8日至2015年7月20日开展。
- 共567例患者随机分配至补脾益肾方组(n=283)或氯沙坦组(n=284),549例(97%)纳入最终分析。
- 干预48周,主要结局为48周内eGFR斜率变化。
主要发现
- 补脾益肾方组48周内eGFR斜率下降更慢,尤其前12周(组间均差-2.25 ml/min/1.73 m2/年,95%CI:-4.03,-0.47)。
- 补脾益肾方组复合终点(全因死亡、血肌酐倍增、ESKD、卒中或心血管事件)风险更低(校正HR=0.61,95%CI:0.44,0.85)。
- 两组不良事件发生率无显著差异。
关键数值与推荐
- 主要结局:48周eGFR斜率组间均差-2.25 ml/min/1.73 m2/年(95%CI:-4.03,-0.47)。
- 复合终点:校正HR=0.61(95%CI:0.44,0.85)。
临床怎么用
- 对于非糖尿病CKD4患者,可考虑使用补脾益肾方以延缓肾功能下降。
- 使用补脾益肾方时需关注长期疗效,目前证据支持前12周及48周内的获益。
局限性
- 需要更长随访时间评估长期疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chinese herbal medicine (CHM) might have benefits in patients with non-diabetic chronic kidney disease (CKD), but there is a lack of high-quality evidence, especially in CKD4. This study aimed to assess the efficacy and safety of Bupi Yishen Formula (BYF) vs. losartan in patients with non-diabetic CKD4. This trial was a multicenter, double-blind, double-dummy, randomized controlled trial that was carried out from 11-08-2011 to 07-20-2015. Patients were assigned (1:1) to receive either BYF or losartan for 48 weeks. The primary outcome was the change in the slope of the estimated glomerular filtration rate (eGFR) over 48 weeks. The secondary outcomes were the composite of end-stage kidney disease, death, doubling of serum creatinine, stroke, and cardiovascular events. A total of 567 patients were randomized to BYF (n = 283) or losartan (n = 284); of these, 549 (97%) patients were included in the final analysis. The BYF group had a slower renal function decline particularly prior to 12 weeks over the 48-week duration (between-group mean difference of eGFR slopes: -2.25 ml/min/1.73 m2/year, 95% confidence interval [CI]: -4.03,-0.47), and a lower risk of composite outcome of death from any cause, doubling of serum creatinine level, end-stage kidney disease (ESKD), stroke, or cardiovascular events (adjusted hazard ratio = 0.61, 95%CI: 0.44,0.85). No significant between-group differences were observed in the incidence of adverse events. We conclude that BYF might have renoprotective effects among non-diabetic patients with CKD4 in the first 12 weeks and over 48 weeks, but longer follow-up is required to evaluate the long-term effects. Clinical Trial Registration: http://www.chictr.org.cn, identifier ChiCTR-TRC-10001518.
引用
- Mao W, Yang N, Zhang L, et al. Bupi Yishen Formula Versus Losartan for Non-Diabetic Stage 4 Chronic Kidney Disease: A Randomized Controlled Trial. Front Pharmacol. 2021. PMID: 33708125. doi:10.3389/fphar.2020.627185
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。